"I have great respect for Romanians who managed to overcomeobstacles facing them over the centuries," says Brendan O'Brien,44, head of the local subsidiary of the world's biggest drugmanufacturer Pfizer, in his first interview to the Romanianpress.
American O'Brien, who admits he has studied European history,came to the helm of Pfizer Romania at the beginning of this yearand estimates integration of Wyeth, a company acquired atinternational level, could be completed by the end of 2010.
"Our target is to complete integration by the end of this year,have a clear picture of how we will be operating. I think Romastru(distributor of Wyeth products i.e.) and Pfizer will continue towork together, but we are now deciding how," said Brendan O'Brien,country manager of Pfizer Romania, in his first interview sincetaking over the position in January this year.
Last year Pfizer, the world's biggest drug manufacturer, tookover rival Wyeth in a 68 billion-dollar transaction. In Romania theintegration of the two companies' operations is special in thatWyeth does not have its own Romanian office, with its productsbeing distributed by Romastru trading, which also conductedpromotional and marketing operations.
In 2009 Pfizer (Wyeth included) ranked third on the Romanianpharmaceutical market with a 532.1 million-RON (122.6 million-euro)turnover and a 6.6% market share, according to data of marketresearch and surveys Cegedim.
"I would like to see Pfizer at no. 1 in Romania within the nextthree years," O'Brien when ZF asked if his target was to make thecompany no. 1.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
